Dallas Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-07-2024
- Paid Up Capital ₹ 2.50 Cr
as on 24-07-2024
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.28 Cr
as on 24-07-2024
- Revenue -47.93%
(FY 2023)
- Profit -787.50%
(FY 2023)
- Ebitda -61.54%
(FY 2023)
- Net Worth -75.20%
(FY 2023)
- Total Assets 6.24%
(FY 2023)
About Dallas Drugs
The Corporate was formerly known as Friska Foods Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹11.28 Cr.
Rajesh Gupta and Anil Kumar serve as directors at the Company.
- CIN/LLPIN
U15400CH2012PTC033748
- Company No.
033748
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dallas Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar  | Director | 29-Sep-2018 | Current |
| Rajesh Gupta | Director | 29-Sep-2018 | Current |
Financial Performance and Corporate Structure Insights of Dallas Drugs.
Dallas Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 47.93% decrease. The company also saw a substantial fall in profitability, with a 787.5% decrease in profit. The company's net worth observed a substantial decline by a decrease of 75.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dallas Drugs?
In 2023, Dallas Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 20 Apr 2019 | ₹11.28 Cr | Open |
How Many Employees Work at Dallas Drugs?
Dallas Drugs has a workforce of 21 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dallas Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dallas Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
